WANG Chuanlan, YU Jianfeng, JI Yan. Clinical efficacy of Huanshaodan combined with western medicine in treating chronic cerebral ischemic vertigo of spleen-kidney deficiency[J]. Journal of Clinical Medicine in Practice, 2023, 27(2): 122-125. DOI: 10.7619/jcmp.20222471
Citation: WANG Chuanlan, YU Jianfeng, JI Yan. Clinical efficacy of Huanshaodan combined with western medicine in treating chronic cerebral ischemic vertigo of spleen-kidney deficiency[J]. Journal of Clinical Medicine in Practice, 2023, 27(2): 122-125. DOI: 10.7619/jcmp.20222471

Clinical efficacy of Huanshaodan combined with western medicine in treating chronic cerebral ischemic vertigo of spleen-kidney deficiency

  • Objective To observe the clinical effect of Huanshaodan combined with western medicine in treating chronic cerebral ischemic vertigo of spleen-kidney deficiency type.
    Methods A total of 60 patients with chronic cerebral ischemic vertigo of spleen and kidney deficiency type were selected as study objects, and were randomly divided into control group and combination group, with 30 cases in each group. The patients in the control group were treated with betahistine and citicoline, and those in the combination group orally taken Huanshaodan based on the control group, the treatment was lasted 4 courses of treatment. The therapeutic effect, TCM symptom score and plasma homocysteine (Hcy) level before and after treatment were observed and compared between the two groups.
    Results Before treatment, there were statistically significant differences in scores of TCM symptoms between two groups (P < 0.05); after treatment, scores of TCM symptoms in two groups were lower than before treatment, and scores of dizziness, fatigue, waist and knee weakness, forgetfulness and attack frequency in the combination group were lower than those in the control group (P < 0.05). The total remarked efficiency of the combination group was 60.00% (18/30), which was higher than 36.67% (11/30) of the control group (P < 0.05). The total effective rate of the combined group was 93.33% (28/30), which was higher than 83.33% (25/30) of the control group, but the differences showed not statistically significant (P>0.05). Before treatment, there was no significant difference in plasma Hcy level between two groups (P>0.05). After treatment, plasma Hcy levels in combination group and control group were (13.14±5.83) and (16.75±7.73) μmol/L, which were lower than (20.79±6.52) and (18.56±7.69) μmol/L, respectively before treatment, and the plasma Hcy level in the combination group was lower than that in control group (P < 0.05).
    Conclusion Huanshaodan treatment on the basis of western medicine can better relieve the clinical symptoms of chronic cerebral ischemia vertigo patients with spleen and kidney deficiency, significantly reduce the level of plasma Hcy, and significantly improve the prognosis of patients.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return